SCHEMBL30474222

SCHEMBL30474222

CC(C)(C)OC(=O)N1CCc2cc(Br)c(O)nc2C1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.54
NR1H2 P55055 2/20 0.50
MAPT P10636 2/20 0.45
PARP1 P09874 1/20 0.41
TNKS2 Q9H2K2 1/20 0.41
PARP2 Q9UGN5 1/20 0.41
KCNH2 Q12809 1/20 0.39
MAPK1 P28482 2/20 0.39
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
MKNK1 Q9BUB5 3/20 0.38
ADORA1 P30542 1/20 0.37
GRAMD1A Q96CP6 1/20 0.37
F12 P00748 1/20 0.37
HPGDS O60760 1/20 0.37
GPR119 Q8TDV5 1/20 0.37
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30474173 1.00 ESR2 (0.54) ESR2NR1H2MAPTPARP1TNKS2
SCHEMBL4524243 0.91 ESR2 (0.49) ESR2NR1H2MAPTKCNH2GPR119
SCHEMBL30474291 0.85 ESR2 (0.54) ESR2NR1H2MAPTPARP1TNKS2
SCHEMBL30474275 0.85 ESR2 (0.54) ESR2NR1H2MAPTPARP1TNKS2
SCHEMBL30474190 0.85 ESR2 (0.57) ESR2NR1H2MAPTPARP1TNKS2
SCHEMBL31335731 0.85 ESR2 (0.48) ESR2NR1H2MAPTPARP1TNKS2
SCHEMBL30474324 0.84 ESR2 (0.53) ESR2NR1H2MAPTPARP1TNKS2
SCHEMBL31413115 0.84 ESR2 (0.53) ESR2NR1H2MAPTPARP1TNKS2
SCHEMBL31413070 0.83 ESR2 (0.52) ESR2NR1H2MAPTPARP1TNKS2
SCHEMBL30474207 0.83 ESR2 (0.52) ESR2NR1H2MAPTPARP1TNKS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250109148-A1 HETEROCYCLIC GLP-1 AGONISTS SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) 2025-04-03 US disclosed
CN-119343339-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2025-01-21 CN disclosed
EP-4469444-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2024-12-04 EP disclosed
WO-2023138684-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO , INC. (US) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250109148-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR ESR2 447/4885NR1H2 456/4885MAPT 3323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.